Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JIN-A02 |
Synonyms | |
Therapy Description |
JIN-A02 is a fourth-generation EGFR inhibitor that targets EGFR mutations including C797S, which potentially results in decreased tumor growth (Ann Oncol 2022, Vol 33, Supp 7:S1010-S1011). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JIN-A02 | JIN A02|JINA02 | EGFR Inhibitor 4th gen 16 | JIN-A02 is a fourth-generation EGFR inhibitor that targets EGFR mutations including C797S, which potentially results in decreased tumor growth (Ann Oncol 2022, Vol 33, Supp 7:S1010-S1011). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05394831 | Phase Ib/II | JIN-A02 | A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | Recruiting | USA | 2 |